| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2018 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 2,500 | $6.04 | $15,100.00 | +1.0% | |
| Jun 26, 2018 | AVDL Avadel Pharmaceuticals Plc | Divis Greg J71 | See Remarks | Buy | 16,000 | $6.00 | $96,000.00 | +48.3% | |
| Jun 26, 2018 | AVDL Avadel Pharmaceuticals Plc | Kanan Michael F | See Remarks | Buy | 1,967 | $5.70 | $11,211.90 | +5.5% | |
| Jun 25, 2018 | AVDL Avadel Pharmaceuticals Plc | Flynn James E62 | 10% Owner, *possible Member Of 10% Group | Sell | 114,034 | $5.99 | $683,314.53 | -10.7% | |
| Jun 25, 2018 | LNTH Lantheus Holdings, Inc. | McHugh Julie53 | Director | Sell | 4,560 | $14.72 | $67,123.20 | -23.6% | |
| Jun 21, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 7,205 | $60.00 | $432,323.06 | -49.0% | |
| Jun 21, 2018 | COLL Collegium Pharmaceutical, Inc | Brannelly Paul | Executive Vice President &CFO | Sell | 10,000 | $27.92 | $279,165.00 | -3.8% | |
| Jun 21, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 60,000 | $38.57 | $2,314,224.00 | +2.0% | |
| Jun 21, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 30,000 | $47.56 | $1,426,745.00 | -16.7% | |
| Jun 21, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 30,000 | $47.56 | $1,426,745.00 | -16.7% | |
| Jun 20, 2018 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 23,000 | $105.00 | $2,415,000.00 | -21.7% | |
| Jun 18, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Schwabe Stefan K.F. | Executive VP R&D, CMO | Sell | 60,000 | $54.39 | $3,263,352.00 | -96.8% | |
| Jun 18, 2018 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 134,094 | $61.00 | $8,179,945.14 | -68.1% | |
| Jun 15, 2018 | MRMD Marimed Inc. | Kidrin Thomas | Director | Sell | 32,994 | $3.56 | $117,458.64 | -1.8% | |
| Jun 15, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $86.65 | $15,597,720.00 | -0.1% | |
| Jun 14, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 107,698 | $86.31 | $9,295,414.38 | - | |
| Jun 14, 2018 | LLY Eli Lilly & Co | Skovronsky Daniel | SVP, CSO, And Pres. Lrl | Buy | 10,000 | $86.22 | $862,200.00 | +22.1% | |
| Jun 14, 2018 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 86,963 | $99.48 | $8,650,738.28 | -25.9% | |
| Jun 13, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 11,104 | $86.27 | $957,953.18 | - | |
| Jun 13, 2018 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 15,000 | $99.24 | $1,488,549.00 | -5.4% | |
| Jun 13, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 30,000 | $46.44 | $1,393,200.00 | -25.5% | |
| Jun 13, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 30,000 | $46.44 | $1,393,200.00 | -25.5% | |
| Jun 12, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 15,000 | $16.52 | $247,842.00 | -33.4% | |
| Jun 12, 2018 | ALKS Alkermes Plc. | Frates James M83 | SVP, Alks Inc; CFO Alks | Sell | 16,842 | $50.00 | $842,179.16 | -31.1% | |
| Jun 12, 2018 | COLL Collegium Pharmaceutical, Inc | Fleming Alison B | Chief Technology Officer | Sell | 4,096 | $27.00 | $110,592.00 | -7.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.